Balyasny Asset Management
WHWK

Balyasny Asset Management’s Whitehawk Therapeutics WHWK Stock Holding History

Balyasny Asset Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.9M Buy
+550,441
New +$1.72M ﹤0.01% 1803
2022
Q2 		– Sell
-11,705
Closed -$199K – 3269
2022
Q1 		$199K Buy
+11,705
New +$224K ﹤0.01% 2027

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Balyasny Asset Management's WHWK Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Whitehawk Therapeutics (WHWK) in Q1 2026: 550,441 shares worth $1.9M. The stake represents ﹤0.01% of the portfolio and ranks #1803 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in WHWK as recently as Q1 2022.

Balyasny Asset Management first reported a position in WHWK in Q1 2022 and has held it in 2 quarters since. 62 funds tracked by Wall St. Rank hold WHWK as of Q1 2026.

  • Balyasny Asset Management held 550,441 shares of Whitehawk Therapeutics worth $1.9M as of Q1 2026.
  • Whitehawk Therapeutics was a new Balyasny Asset Management position in Q1 2026.
  • Whitehawk Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1803 holding.
  • Balyasny Asset Management first reported a position in Whitehawk Therapeutics in Q1 2022 and has held it in 2 quarters since.
  • 62 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.